Priti V Mandalaywala, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Massena, NY 13662 Phone: 315-769-4644 Fax: 315-842-3050 |
News Archive
Living Cell Technologies Limited today announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson's disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL.
Researchers in the United States have found that older patients about to undergo major surgery, who have either a high or low red blood cell count, are more at risk for heart attacks or even death following the operation.
LyoTechnica, LLC has announced that it has been established to provide contract drug development services for injectable pharmaceuticals. The company and its affiliates bring over 80 years of combined experience in lyophilization and liquid dosage form development as well as over 100 years experience in commercial scale manufacturing of parenteral drugs. The company offers analytical and formulation development, manufacturing of sterile stability batches and stability testing services.
The condition (bipolar I and II) affects approximately 8 million Americans, who have relied on a combination of drugs to manage their symptoms, and who remain at high risk of committing suicide because of the difficulty in treating the disorder.
› Verified 1 days ago